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Objectives
To evaluate safety and efficacy of tocilizumab treatment
in children with systemic onset of juvenile idiopathic
arthritis (JIA).
Methods
A retrospective observational study on JIA patients tak-
ing tocilizumab (n=39). Tocilizumab was administered
intravenously at a dose of 8 mg/kg every 2 weeks during
2 months then every 4 weeks. All patients received
DMARDs. Efficacy end points included the American
C o l l e g eo fR h e u m a t o l o g y( A C R )P e d i a t r i c3 0( P e d i3 0 ) ,
Pedi 50, Pedi 70, and Pedi 90 criteria for improvement.
Results
A total of 39 patients (21 boys and 18 girls) were
included in this Median age was 7,5 years (range; 3 to
15 years) and median disease duration was 4,2 years
(range; 0.5 to 8,3 years). A total of 16 of the 39
patients (25%) entered 52 weeks of continuous tocilizu-
mab treatment. The frequently observed non-severe
adverse events were nasopharyngitis, upper respiratory
tract infection and gastroenteritis. No cases of oppor-
tunistic infections, malignancies, autoimmune diseases,
o rd e a t hw e r er e p o r t e d .O n ec a s eo fp n e u m o n i a .2 1
patients had incidences of neutropenia.The ACR Pedi
30, 50, 70 and 90 were achieved by 82%,50%, 27% and
12% of patients at Week 4 (N=36), and by 100%, 81%,
69%, and 50% of patients at Week 24 (N=18), and by
100%, 85%, 78%, and 57% of patients at Week 52
(N=16), respectively.
Conclusion
Clinical improvements in the signs and symptoms of
systemic JIA were also achieved in favorable levels in
tocilizumab in the treatment of children with JIA.
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